Candel Therapeutics, INC. (CADL) — 10-Q Filings

10-Q Filings (6)

• Candel Therapeutics Narrows Loss Amid R&D Spend, Cash Burn Continues — Nov 13, 2025 Risk: high
  Candel Therapeutics, Inc. (CADL) reported a net loss of $8.686 million for the nine months ended September 30, 2025, a significant improvement from the $41.104
• CADL Swings to Profit on Warrant Revaluation, Boosts Capital — Aug 14, 2025 Risk: high
  Candel Therapeutics, Inc. (CADL) reported a net income of $2.583 million for the six months ended June 30, 2025, a significant improvement from a net loss of $3
• Candel Therapeutics Files Q1 2025 10-Q — May 13, 2025 Risk: medium
  Candel Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its activities, including its At-The-Market Offering from
• Candel Therapeutics Q3 2024 Update — Nov 14, 2024 Risk: medium
  Candel Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported research and development expenses for the third quarter
• Candel Therapeutics Files Q2 2024 10-Q — Aug 13, 2024 Risk: medium
  Candel Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial position and business operations. Key agreem
• Candel Therapeutics, Inc. Files 10-Q for Q1 2024 — May 14, 2024 Risk: medium
  Candel Therapeutics, Inc. (CADL) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Candel Therapeutics, Inc. filed a 10-Q report for the period endi

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX